2. Search Result
Search Result
Results for "

OA

" in MedChemExpress (MCE) Product Catalog:

61

Inhibitors & Agonists

9

Peptides

4

Inhibitory Antibodies

17

Natural
Products

20

Recombinant Proteins

2

Isotope-Labeled Compounds

2

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16268
    Kartogenin
    Maximum Cited Publications
    31 Publications Verification

    KGN

    		 TGF-beta/Smad Inflammation/Immunology
    Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
    Kartogenin
  • HY-N1584
    Halofuginone
    Maximum Cited Publications
    20 Publications Verification

    RU-19110

    		 DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone
  • HY-N1584A
    Halofuginone hydrobromide
    Maximum Cited Publications
    20 Publications Verification

    RU-19110 hydrobromide

    		 DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrobromide
  • HY-B2082
    Fursultiamine

    		VEGFR Ferroportin NF-κB Mitochondrial Metabolism Neurological Disease Inflammation/Immunology Cancer
    Fursultiamine is a vitamin B1 derivative, has anti-nociceptive and antineoplastic activity. Fursultiamine can be used for vitamin B1?deficiency, osteoarthritis (OA) and cancer research .
    Fursultiamine
  • HY-100359
    CL-82198
    5+ Cited Publications

    		 MMP Inflammation/Immunology Cancer
    CL-82198 is a selective inhibitor of MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs . CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression .
    CL-82198
  • HY-N0866
    20-Deoxyingenol
    5 Publications Verification

    		 Autophagy Inflammation/Immunology
    20-Deoxyingenol, a diterpene, is isolated from the roots of Euphorbia kansui. 20-Deoxyingenol can promote autophagy and lysosomal biogenesis by promoting the nuclear translocation of transcription factor EB (TFEB) in vitro. 20-Deoxyingenol can be used for the research of osteoarthritis (OA) .
    20-Deoxyingenol
  • HY-162514
    BBC0403

    		Epigenetic Reader Domain Inflammation/Immunology
    BBC0403 is a selective BRD2 inhibitor with Kds of 7.64 μM and 41.37 μM for BRD2 (BD2) and BRD2 (BD1), respectively. BBC0403 exhibitS higher binding specificity for BRD2 compared to BRD3 and BRD4. BBC0403 has the potential for osteoarthritis (OA) research .
    BBC0403
  • HY-13507
    Lumiracoxib
    1 Publications Verification

    COX-189

    		 COX Metabolic Disease Inflammation/Immunology Cancer
    Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06?μM . Lumiracoxib acts as a nonselective NSAID with?anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
    Lumiracoxib
  • HY-N0665
    Specnuezhenide
    1 Publications Verification

    (8E)-Nuezhenide

    		 NF-κB Wnt Inflammation/Immunology
    Specnuezhenide ((8E)-Nuezhenide) is isolated from the fruits of Ligustrum lucidum. Specnuezhenide ((8E)-Nuezhenide) can inhibit IL-1β-induced inflammation in chondrocytes via inhibition of NF-κB and wnt/β-catenin signaling. Specnuezhenide ((8E)-Nuezhenide) exerts anti-inflammatory effects in a rat model of osteoarthritis (OA) .
    Specnuezhenide
  • HY-112546
    MMP-2 Inhibitor I

    		MMP Cancer
    MMP-2 Inhibitor I (OA-Hy) is a potent MMP-2 inhibitor with a Ki of 1.7 μM .
    MMP-2 Inhibitor I
  • HY-129467
    (Rac)-Idroxioleic acid

    2-Hydroxyoleic acid; 2-OHOA; LAM561

    		 Apoptosis Cancer
    (Rac)-Idroxioleic acid (2-Hydroxyoleic acid) is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid has anti-tumor effect .
    (Rac)-Idroxioleic acid
  • HY-P99627
    Frunevetmab

    NV-02; PG110; ABT-110

    		 Trk Receptor Inflammation/Immunology
    Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats .
    Frunevetmab
  • HY-W016819B
    5-Fluoroorotic acid monohydrate

    5-Fluorouracil-6-carboxylic acid Monohydrate; 5-FOA; 5-fluoro OA

    		 Thymidylate Synthase Parasite Infection
    5-Fluoroorotic acid monohydrate is the monohydrate salt form of 5-Fluoroorotic acid (HY-W016819). 5-Fluoroorotic acid monohydrate is the inhibitor for thymidylate synthase that acts as a selective agent in yeast molecular genetics. 5-Fluoroorotic acid monohydrate exhibits antimalarial activity .
    5-Fluoroorotic acid monohydrate
  • HY-N8307
    Syringaresinol

    		NO Synthase NF-κB Akt AMPK Calcium Channel Inflammation/Immunology
    Syringaresinol is a lignan-type phytochemical with anti-inflammatory activities. Syringaresinol inhibits the NF-κB and AKT signaling pathway in IL-1β-activated mouse chondrocytes. Syringaresinol increases phosphorylation of AMPK, eNOS, and intracellular Ca 2+ levels in HUVECs. Syringaresinol attenuates osteoarthritis progression in mice with Destabilization of the Medial Meniscus (DMM)-induced osteoarthritis. Syringaresinol can be used for the study of osteoarthritis (OA) .
    Syringaresinol
  • HY-N1966
    (E)-Osmundacetone
    2 Publications Verification

    		 p38 MAPK PPAR Cancer
    (E)-Osmundacetone is an inhibitor of the MAPK pathway. (E)-Osmundacetone inhibits the activation of the MAPK signaling pathway and restores the expression of PPARα/ACOX1. (E)-Osmundacetone abrogates abnormal cell proliferation, migration and liver metastasis induced by PTPRO silencing in colorectal cancer cells. (E)-Osmundacetone blocks OA-RD17-mediated activation of the MAPK signaling pathway, thereby reducing macrophage proliferation and migration. (E)-Osmundacetone is applicable to relevant research on colorectal cancer .
    (E)-Osmundacetone
  • HY-108672
    NF157

    		P2Y Receptor Inflammation/Immunology
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively . NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA) .
    NF157
  • HY-P99195
    Fasinumab

    REGN-475; SAR-164877

    		 Trk Receptor Inflammation/Immunology
    Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
    Fasinumab
  • HY-N4090
    Vicenin 3

    		Angiotensin-converting Enzyme (ACE) ERK MMP ADAMTS p38 MAPK Cardiovascular Disease
    Vicenin 3 is an angiotensin-converting enzyme (ACE) inhibitor (IC50 = 46.91 μM) that can be isolated from the aerial parts of Desmodium styracifolium. Vicenin 3 ameliorates IL-1β-induced extracellular matrix degradation in SW1353 chondrocytes by regulating the MAPK pathway. Vicenin 3 can be used for the study of osteoarthritis (OA) and hypertension .
    Vicenin 3
  • HY-N8060A
    Orotidine 5′-monophosphate trisodium
    1 Publications Verification

    Orotidine monophosphate trisodium; Orotidylic acid trisodium

    		 Endogenous Metabolite DNA/RNA Synthesis Metabolic Disease
    Orotidine 5'-monophosphate trisodium is a pyrimidine nucleotide. Orotidine 5'-monophosphate trisodium is synthesized via the de novo synthesis pathway for DNA synthesis in a large number of microorganisms including M. tuberculosis, S. cerevisiae, S. typhimurium and P. falciparum to name a few. The synthesis of orotidine 5'-monophosphate trisodium uses phosphoribosyl pyrophosphate (PRPP) and orotic acid (OA) as the substrates catalyzed by orotate phosphoribosyltransferase (OPRT) .
    Orotidine 5′-monophosphate trisodium
  • HY-P990071
    Fepixnebart

    LY-3016859

    		 EGFR Neurological Disease Metabolic Disease Inflammation/Immunology
    Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .
    Fepixnebart
  • HY-122624
    MMP13-IN-2

    		MMP Inflammation/Immunology
    MMP13-IN-2 is a potent, selective and orally active MMP-13 inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC50=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE. MMP13-IN-2 has the ability to block the release of collagen from cartilage in vitro. MMP13-IN-2 has the potential for collagenase related disease research .
    MMP13-IN-2
  • HY-N0801
    Polygalacic acid

    		MMP Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    Polygalacic acid, is a triterpene, isolated from the root of Polygala tenuifolia Willd. Polygalacic acid inhibits MMP expression. Polygalacic acid may have a therapeutic effect in Osteoarthritis (OA) treatment . Polygalacic acid exerts a significant neuroprotective effect on cognitive impairment, PA improves cholinergic system reactivity by inhibiting acetylcholinesterase (AChE) activity, increasing choline acetyltransferase (ChAT) activity, and elevating levels of acetylcholine (Ach) in the hippocampus and frontal cortex .
    Polygalacic acid
  • HY-N1584C
    Halofuginone lactate
    15+ Cited Publications

    RU-19110 lactate

    		 DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone lactate, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone lactate
  • HY-16268A
    Kartogenin sodium
    Maximum Cited Publications
    31 Publications Verification

    KGN sodium

    		 TGF-beta/Smad Inflammation/Immunology
    Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin sodium induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin sodium also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin sodium is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin sodium promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
    Kartogenin sodium
  • HY-P11208C
    mNLS-CPP-WSTF TFA

    		GABA Receptor Inflammation/Immunology
    mNLS-CPP-WSTF TFA is the trifluoroacetate salt of mNLS-CPP-WSTF (HY-P11208). mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .
    mNLS-CPP-WSTF TFA
  • HY-174156
    Y2641

    		RANKL/RANK TNF Receptor Inflammation/Immunology
    Y2641, a etrahydro-β-carboline derivative, is an orally active dual RANKL/TNF-α inhibitor with Kd values of 3.984 μM and 18.59 μM for RANKL and TNF-α, respectively. Y2641 inhibits RANKL-induced osteoclastogenic and has anti-inflammatory and cartilage destruction. Y2641 can be used for study of osteoarthritis .
    Y2641
  • HY-N1584R
    Halofuginone (Standard)

    RU-19110 (Standard)

    		 Reference Standards DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (Standard) is the analytical standard of Halofuginone. This product is intended for research and analytical applications. Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone (Standard)
  • HY-N1584AR
    Halofuginone hydrobromide (Standard)

    RU-19110 hydrobromide (Standard)

    		 Reference Standards DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (hydrobromide) (Standard) is the analytical standard of Halofuginone (hydrobromide). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrobromide (Standard)
  • HY-179177
    AO-365/43472821

    		DYRK CDK Tau Protein Amyloid-β Neurological Disease
    AO-365/43472821 is a selective, brain-penetrant Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor (IC50 = 0.29 μM) and shows a significant inhibitory effect on (CDC-like kinase 1) CLK1 (IC50 = 0.08 μM). AO-365/43472821 could protect the human neuroblastoma cell line SH-SY5Y from Okadaic acid (HY-N6785) (OA)-induced injury. AO-365/43472821 decreased tau (pSer396)/tau and Aβ1-42 protein expression. AO-365/43472821 can be used for the study of Alzheimer's disease .
    AO-365/43472821
  • HY-P2414
    MMP-13 Substrate

    		MMP Inflammation/Immunology
    MMP-13 Substrate is a substrate of MMP-13. MMP-13 Substrate can be used for the research of osteoarthritis (OA) .
    MMP-13 Substrate
  • HY-P11208
    mNLS-CPP-WSTF

    		GABA Receptor Inflammation/Immunology
    mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .
    mNLS-CPP-WSTF
  • HY-125415
    PF-4693627

    		PGE synthase Inflammation/Immunology
    PF-4693627 is a potent, selective and orally bioavailable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor (IC50=3 nM) for the treatment of inflammation caused by osteoarthritis (OA) and rheumatoid arthritis (RA) .
    PF-4693627
  • HY-121936A
    Yohimbic acid hydrate

    		Adrenergic Receptor Drug Derivative Cardiovascular Disease Inflammation/Immunology Cancer
    Yohimbic acid hydrate is a derivative of Yohimbine Hydrochloride (HY-N0127). Yohimbic acid hydrate exhibits vasodilatory and anticancer activities. Yohimbic acid hydrate can be used for the research of cancer, inflammation and cardiovascular disease .
    Yohimbic acid hydrate
  • HY-N1584B
    Halofuginone hydrochloride
    15+ Cited Publications

    RU-19110 hydrochloride

    		 Calcium Channel DNA/RNA Synthesis Parasite Sodium Channel TGF-beta/Smad Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrochloride
  • HY-172535
    Lipid OA2 dihydrochloride

    		Lipase Inflammation/Immunology Cancer
    Lipid OA2 dihydrochloride is an ionizable cationic lipid that can be used to prepare single-component lipid nanoparticles for siRNA delivery. Lipid OA2 dihydrochloride can effectively deliver SOCS1-siRNA to dendritic cells, silence the SOCS1 gene, and enhance their antigen-presenting ability and pro-inflammatory factor secretion capacity .
    Lipid OA2 dihydrochloride
  • HY-P991324
    MEDI-7352

    		Trk Receptor TNF Receptor Inflammation/Immunology
    MEDI-7352 is a human bispecific antibody (bsAb) targeting NGF/bNGF & TNF. MEDI-7352 can be used in osteoarthritis (OA) pain research .
    MEDI-7352
  • HY-N4090R
    Vicenin 3 (Standard)

    		Reference Standards Angiotensin-converting Enzyme (ACE) ERK MMP p38 MAPK Cardiovascular Disease
    Vicenin 3 (Standard) is the analytical standard of Vicenin 3. Vicenin 3 is an angiotensin-converting enzyme (ACE) inhibitor (IC50 = 46.91 μM) that can be isolated from the aerial parts of Desmodium styracifolium. Vicenin 3 ameliorates IL-1β-induced extracellular matrix degradation in SW1353 chondrocytes by regulating the MAPK pathway. Vicenin 3 can be used for the study of osteoarthritis (OA) and hypertension .
    Vicenin 3 (Standard)
  • HY-P2414A
    MMP-13 Substrate TFA

    		MMP Inflammation/Immunology
    MMP-13 Substrate TFA is a substrate of MMP-13. MMP-13 Substrate TFA can be used for the research of osteoarthritis (OA) .
    MMP-13 Substrate TFA
  • HY-173165
    OA-Br-1

    3-O-(6-Bromo-D-mannosyl)-28-acylamino-n-caprOAte methyl oleanolic acid

    		 Phosphatase Apoptosis Cancer
    OA-Br-1 is an orally active and selective inhibitor of PTP1B with an IC50 value of 7.08 μM. OA-Br-1 induces apoptosis. OA-Br-1 has broad spectrum anti-proliferative activity against cancer cells, and plays an anti-breast cancer role through the PTP1B/PI3K/AKT signaling pathway both in vitro and in vivo .
    OA-Br-1
  • HY-W746555S
    Metazachlor metabolite BH479-4-d9

    Metazachlor OA-d9; Metazachlor oxalic acid-d9

    		 Isotope-Labeled Compounds Others
    Metazachlor metabolite BH479-4-d9 (Metazachlor OA-d9) is deuterium labeled Metazachlor Oxalic Acid .
    Metazachlor metabolite BH479-4-d9
  • HY-N0665R
    Specnuezhenide (Standard)

    (8E)-Nuezhenide (Standard)

    		 Reference Standards NF-κB Wnt Inflammation/Immunology
    Specnuezhenide (Standard) is the analytical standard of Specnuezhenide. This product is intended for research and analytical applications. Specnuezhenide ((8E)-Nuezhenide) is isolated from the fruits of?Ligustrum lucidum. Specnuezhenide ((8E)-Nuezhenide) can inhibit IL-1β-induced inflammation in chondrocytes via inhibition of NF-κB and wnt/β-catenin signaling. Specnuezhenide ((8E)-Nuezhenide) exerts anti-inflammatory effects in a rat model of osteoarthritis (OA) .
    Specnuezhenide (Standard)
  • HY-B2082R
    Fursultiamine (Standard)

    		VEGFR Reference Standards Ferroportin NF-κB Mitochondrial Metabolism Neurological Disease Inflammation/Immunology Cancer
    Fursultiamine (Standard) is the analytical standard of Fursultiamine. This product is intended for research and analytical applications. Fursultiamine is a vitamin B1 derivative, has anti-nociceptive and antineoplastic activity. Fursultiamine can be used for vitamin B1 deficiency, osteoarthritis (OA) and cancer research .
    Fursultiamine (Standard)
  • HY-146981
    α-Glucosidase-IN-3

    		Glycosidase Inflammation/Immunology
    α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivativ eagainst α-glucosidase(IC50=0.35 µM) and α-amylase.
    α-Glucosidase-IN-3
  • HY-129467A
    (Rac)-Idroxioleic acid sodium

    2-Hydroxyoleic acid sodium; 2-OHOA sodium; LAM561 sodium

    		 Apoptosis Cancer
    (Rac)-Idroxioleic acid (2-Hydroxyoleic acid) sodium is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid sodium has anti-tumor effect .
    (Rac)-Idroxioleic acid sodium
  • HY-149377
    MMP13-IN-4

    		MMP Metabolic Disease
    MMP13-IN-4 (compound 13) is a potent and selective inhibitor of MMP-13 (IC50=14.6 μM)，involved in osteoarthritis (OA) .
    MMP13-IN-4
  • HY-146984
    α-Amylase-IN-2

    		Glycosidase Inflammation/Immunology
    α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivative against α-glucosidase (IC50=1.28 µM) and α-amylase (IC50=3.8 µM) .
    α-Amylase-IN-2
  • HY-151524
    Cathepsin K inhibitor 3

    		Cathepsin Inflammation/Immunology
    Cathepsin K inhibitor 3 (compound 23) is a highly selective cathepsin K inhibitor with an IC50 value of 0.5 nM. Cathepsin K inhibitor 3 has a favorable pharmacokinetic profile and may be used in osteoarthritis (OA) disease studies .
    Cathepsin K inhibitor 3
  • HY-149378
    MMP13-IN-5

    		MMP Metabolic Disease
    MMP13-IN-5 (compound 13m) is a potent and selective inhibitor of MMP-2/MMP-13 (IC50=3.6 μM/14.6 μM)，involved in osteoarthritis (OA) .
    MMP13-IN-5
  • HY-129467R
    (Rac)-Idroxioleic acid (Standard)

    2-Hydroxyoleic acid (Standard); 2-OHOA (Standard); LAM561 (Standard)

    		 Reference Standards Apoptosis Cancer
    (Rac)-Idroxioleic acid (Standard) is the analytical standard of (Rac)-Idroxioleic acid. This product is intended for research and analytical applications. (Rac)-Idroxioleic acid (2-Hydroxyoleic acid) is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid has anti-tumor effect[1].
    (Rac)-Idroxioleic acid (Standard)
  • HY-13507R
    Lumiracoxib (Standard)

    COX-189 (Standard)

    		 Reference Standards COX Metabolic Disease Inflammation/Immunology Cancer
    Lumiracoxib (Standard) is the analytical standard of Lumiracoxib. This product is intended for research and analytical applications. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM . Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
    Lumiracoxib (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: